BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
67.98
-3.41 (-4.78%)
At close: Mar 12, 2026, 4:00 PM EDT
68.00
+0.02 (0.03%)
After-hours: Mar 12, 2026, 4:12 PM EDT

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Identifying and Advancing Transformative Medicines to Treat Patients
502.08M221.90M9.30M77.65M69.72M
Identifying and Advancing Transformative Medicines to Treat Patients Growth
126.26%2285.27%-88.02%11.38%745.14%
Total
502.08M221.90M9.30M77.65M69.72M
Total Growth
126.26%2285.27%-88.02%11.38%745.14%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
United States
362.50M13.31M7.90M-69.72M
United States Growth
2622.66%68.57%--745.14%
Europe, Middle East, and Africa (EMEA)
127.03M132.03M55.82K--
Europe, Middle East, and Africa (EMEA) Growth
-3.79%236439.63%---
Asia-Pacific (APAC)
12.55M76.56M1.35M--
Asia-Pacific (APAC) Growth
-83.60%5575.31%---
North America
---76.79M-
Total
502.08M221.90M9.30M76.79M69.72M
Total Growth
126.26%2285.27%-87.89%10.15%745.14%
Source: S&P Global Market Intelligence.